Skip to main content
SpringerLink
Log in

Recombinant human erythropoietin and overall survival

  • Clinical Trials Report
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Conclusions

Although a trend was seen for increased thromboembolic events in patients treated with erythropoietin, there was also a trend for improved survival times in such patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Henke M, Laszig R, Ruebe C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 2003, 362:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  2. Leyland-Jones B, BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003, 4:459–460.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Charles L. Loprinzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loprinzi, C.L. Recombinant human erythropoietin and overall survival. Curr Oncol Rep 7, 269–270 (2005). https://doi.org/10.1007/s11912-005-0049-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-005-0049-2

Keywords

Search

Navigation